Shots:

• Roche & Vaccibody collaborated to assess the combination of VB10.16 + Tecentriq in P-II- for 50 patients with advanced cervical cancer to evaluate its safety- tolerability- immunogenicity and efficacy
• The combination trial agreement is built upon the trial assessing VB10.16 monothx in patients with precancerous cervical lesion. Vaccibody plans for the onset of P-II for the combination in H2’19
• Tecentriq (atezolizumab) is a mAb inhibiting PD-L1 while blocking its interaction with PD-1 and B7.1 receptor. VB10.16 is a DNA vaccine- targeting HPV16 induced malignancies and is evaluated in P-I/IIa study for patients with pre-cancerous HPV16 induced high grade cervical intraepithelial neoplasia

Ref: Vaccibody | Image: Roche